Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
SNTI Senti Biosciences
1.783-0.047-2.57%
Close
01/27 16:00 ET
1.820+0.037+2.09%
Post Mkt Price 01/27 17:29 ET
High
2.110
Open
1.870
Turnover
855.99K
Low
1.710
Pre Close
1.830
Volume
448.53K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Analysts' Price Target Changes for January 27th (AIAPF, CYBBF, DEO, HKMPF, ILMN, SNTI, SVKEF, TGOPY, TPRKY, WZZZY)
Analysts' price target changes for Friday, January 27th: Ascential (OTCMKTS:AIAPF) had its target price boosted by Barclays PLC from GBX 295 ($3.65) to GBX 320 ($3.96). Get Ascential plc alerts: V
Senti Biosciences (SNTI) Receives a Buy From Chardan Capital
Senti Bio Price Target Lowered to $8 From $12 at Chardan
Senti Biosciences Price Target Cut to $3.00/Share From $7.50 by Morgan Stanley
Senti Biosciences Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Maintains Equal-Weight on Senti Biosciences, Lowers Price Target to $3
Morgan Stanley analyst Michael Ulz maintains Senti Biosciences (NASDAQ:SNTI) with a Equal-Weight and lowers the price target from $7.5 to $3.
Senti Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/27/2023 54.64% Morgan Stanley $7.5 → $3 Maintains Equal-Weight 12/16/2022 — JP Morgan Initiates Covera
Inozyme, CVRx Top Healthcare Gainers; Nemaura, Marker Among Losers
Senti Biosciences Launches New Strategic Plan, Sees Cash Runway to 1Q 2024
By Chris Wack Senti Biosciences Inc. said it is launching a new strategic plan, which will focus internal resources on SENTI-202, SENTI-401 and, with potential partners, to continue to pursue the dev
Senti Bio to Focus Resources on SENTI-202, SENTI-401
Company Overview
More
Senti Biosciences, Inc. It was incorporated in Delaware on March 1, 2021. The company aims to design genetic circuits to improve the intelligence of cells and gene therapy to improve its effectiveness, accuracy and persistence in the treatment of a wide range of diseases that cannot be solved by traditional drugs. The company's synthetic biology platform uses ready-made chimeric antigen receptor natural killer cells and is equipped with these genetic circuit technologies for particularly challenging liquid and solid tumor indications. The company's leading projects include SENTI-202 and SENTI-301. SENTI-202 is a logic-gated or + non-ready-made CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells while preserving healthy bone marrow. SENTI-301 is an off-the-shelf CAR-NK cell therapy for the treatment of hepatocellular carcinoma. The company has also demonstrated the breadth of its genetic circuits in ways other than oncology and diseases, and has partnered with Spark and BlueRock to advance these capabilities.
CEO： Dr. Timothy Lu, M.D.,PhD
Market： NASDAQ
Listing Date： 05/26/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet